These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 24830791)

  • 1. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review.
    Cobo-Ibáñez T; Loza-Santamaría E; Pego-Reigosa JM; Marqués AO; Rúa-Figueroa I; Fernández-Nebro A; Cáliz Cáliz R; López Longo FJ; Muñoz-Fernández S
    Semin Arthritis Rheum; 2014 Oct; 44(2):175-85. PubMed ID: 24830791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.
    Borba HH; Wiens A; de Souza TT; Correr CJ; Pontarolo R
    BioDrugs; 2014 Apr; 28(2):211-28. PubMed ID: 24190520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness and safety of biological therapeutics in juvenile-onset systemic lupus erythematosus (JSLE): a systematic review.
    Peterknecht E; Keasey MP; Beresford MW
    Lupus; 2018 Nov; 27(13):2135-2145. PubMed ID: 30336753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review.
    Mahmoud I; Jellouli M; Boukhris I; Charfi R; Ben Tekaya A; Saidane O; Ferjani M; Hammi Y; Trabelsi S; Khalfallah N; Tekaya R; Gargah T; Abdelmoula L
    J Pediatr; 2017 Aug; 187():213-219.e2. PubMed ID: 28602379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review.
    Pego-Reigosa JM; Cobo-Ibáñez T; Calvo-Alén J; Loza-Santamaría E; Rahman A; Muñoz-Fernández S; Rúa-Figueroa Í
    Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1775-85. PubMed ID: 23609987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR; Gordon C
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases.
    Ramos-Casals M; Soto MJ; Cuadrado MJ; Khamashta MA
    Lupus; 2009 Aug; 18(9):767-76. PubMed ID: 19578100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in systemic lupus erythematosus and lupus nephritis.
    Beckwith H; Lightstone L
    Nephron Clin Pract; 2014; 128(3-4):250-4. PubMed ID: 25471633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus.
    Hickman RA; Hira-Kazal R; Yee CS; Toescu V; Gordon C
    Clin Rheumatol; 2015 Feb; 34(2):263-71. PubMed ID: 25564308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus.
    Ale'ed A; Alsonbul A; Al-Mayouf SM
    Rheumatol Int; 2014 Apr; 34(4):529-33. PubMed ID: 24218286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature.
    Hofmann SC; Leandro MJ; Morris SD; Isenberg DA
    Lupus; 2013 Aug; 22(9):932-9. PubMed ID: 23894047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus.
    Oon S; Huq M; Godfrey T; Nikpour M
    Semin Arthritis Rheum; 2018 Oct; 48(2):221-239. PubMed ID: 29426575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis.
    Duxbury B; Combescure C; Chizzolini C
    Lupus; 2013 Dec; 22(14):1489-503. PubMed ID: 24135078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus.
    Vital EM; Wittmann M; Edward S; Md Yusof MY; MacIver H; Pease CT; Goodfield M; Emery P
    Arthritis Rheumatol; 2015 Jun; 67(6):1586-91. PubMed ID: 25707733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis.
    Lan L; Han F; Chen JH
    J Zhejiang Univ Sci B; 2012 Sep; 13(9):731-44. PubMed ID: 22949364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID).
    Witt M; Grunke M; Proft F; Baeuerle M; Aringer M; Burmester G; Chehab G; Fiehn C; Fischer-Betz R; Fleck M; Freivogel K; Haubitz M; Kötter I; Lovric S; Metzler C; Rubberth-Roth A; Schwarting A; Specker C; Tony HP; Unger L; Wassenberg S; Dörner T; Schulze-Koops H;
    Lupus; 2013 Oct; 22(11):1142-9. PubMed ID: 24057058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab treatment for 'rhupus syndrome': clinical and power-Doppler ultrasonographic monitoring of response. A longitudinal pilot study.
    Piga M; Gabba A; Cauli A; Garau P; Vacca A; Mathieu A
    Lupus; 2013 May; 22(6):624-8. PubMed ID: 23559669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus.
    Tanaka Y; Yamamoto K; Takeuchi T; Nishimoto N; Miyasaka N; Sumida T; Shima Y; Takada K; Matsumoto I; Saito K; Koike T
    Mod Rheumatol; 2007; 17(3):191-7. PubMed ID: 17564773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of biologics in childhood systemic lupus erythematosus: a critical systematic review.
    Elshaer R; Jaber S; Odeh N; Arbili L; Al-Mayouf SM
    Clin Rheumatol; 2024 Mar; 43(3):863-877. PubMed ID: 38079010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review.
    Pirone C; Mendoza-Pinto C; van der Windt DA; Parker B; O Sullivan M; Bruce IN
    Semin Arthritis Rheum; 2017 Dec; 47(3):384-396. PubMed ID: 28602359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.